CytoMed Therapeutics Limited Deferred Tax Expense Income
CytoMed Therapeutics Limited (GDTC) reported Deferred Tax Expense Income of SGD 2.41 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:DeferredTaxExpenseIncome · last filed 2026-03-31
| Period end | Deferred Tax Expense Income 12 month | Deferred Tax Expense Income 12 month as first filed |
|---|---|---|
| 2025-12-31 | 2.41M SGD 20-F · filed 2026-03-31 | |
| 2024-12-31 | 1.74M SGD 20-F · filed 2026-03-31 | |
| 2023-12-31 | 1.35M SGD 20-F · filed 2026-03-31 | |
| 2022-12-31 | 972.00K SGD 20-F · filed 2025-04-28 | 972.23K SGD 20-F · filed 2023-05-01 |
| 2021-12-31 | 645.00K SGD 20-F · filed 2024-04-22 | 644.64K SGD 20-F · filed 2023-05-01 |
| 2020-12-31 | 430.10K SGD 20-F · filed 2023-05-01 |